Table 1. Characteristics of studies describing plasma and memory B cell kinetics following immunization with glycoconjugate vaccines.
Study reference | Age (y) |
Number of samples per study time point* |
Vaccine | Carrier protein | Number of priming doses [time since last vaccination] |
Study time points (days) |
---|---|---|---|---|---|---|
Plasma cells | ||||||
Kelly et al.7 | 13–15 | 3–34 | MenCCV | CRM197 | 1 [2–3 y] | 0, 3, 4, 5, 6, 7, 8, 9, 10, 12, 28 |
Clutterbuck et al.6 | 28–44 | 6 | PCV-7† | CRM197 | 1 [1 y] | 0, 6, 7, 15 |
Blanchard Rohner et al.5 | 1 | 5–26 | MenCCV | CRM197 | 3 [8 mo] | 0, 2, 4, 6, 8, 9, 30 |
Kelly et al.8 | 0.17 | 33 | MenCCV | CRM197 | - | 4, 6, 8, 10, 12, 14, 16, 30 |
Kelly et al.8 | 0.33 | 29 | MenCCV | CRM197 | 2 [1 mo] | 4, 6, 8, 10, 12, 14, 16 |
Memory B cells | ||||||
Kelly et al.7 | 13–15 | 3–40 | MenCCV | CRM197 | 1 [2–3 y] | 0, 3, 4, 5, 6, 7, 28, 365 |
Clutterbuck et al.6 | 28–44 | 6 | PCV-7† | CRM197 | 1 [1 y] | 0, 6, 7, 15, 28 |
Blanchard Rohner et al.5 | 1 | 4–28 | MenCCV | CRM197 | 3 [8 mo] | 0, 2, 4, 6, 8, 9, 30 |
Kelly et al.8 | 0.17 | 31 | MenCCV | CRM197 | - | 4, 6, 8, 10, 12, 14, 16, 30 |
Kelly et al.8 | 0.33 | 17 | MenCCV | CRM197 | 2 [1 mo] | 4, 6, 8, 12, 14, 16, 30 |
Perrett et al.9 | 7 | 52 | MenCCV | TT | 3 [6 y] | 0, 7, 28, 365 |
Perrett et al.9 | 8 | 25 | MenCCV | TT | 2 [6 y] | 0, 28, 365 |
Perrett et al.9 | 8.3 | 53 | MenCCV | TT | 1 [6 y] | 0, 7, 28, 365 |
Perrett et al.9 | 9.3 | 30 | MenCCV | TT | 1 [6 y] | 0, 28, 365 |
Perrett et al.9 | 10.3 | 27 | MenCCV | TT | 1 [6 y] | 0, 28, 365 |
Perrett et al.9 | 11.3 | 27 | MenCCV | TT | 1 [6 y] | 0, 28, 365 |
Perrett et al.9 | 12.1 | 29 | MenCCV | TT | 1 [6 y] | 0, 7, 28, 365 |
Number of samples between study time points may differ markedly and the range is given if known, otherwise the total number of samples is shown; †Values from serotype 4 were used to describe plasma and memory B cell kinetics; CRM197, cross-reactive material (non- toxic recombinant form of diphtheria toxin); MenCCV, meningococcal serogroup C conjugate vaccine; PCV-7, 7-valent pneumococcal conjugate vaccine; TT, tetanus toxoid.